Antiperinuclear factor in juvenile rheumatoid arthritis

Gideon Nesher, Terry L Moore, Michael W Grisanti, Eva El-Najdawi, Thomas G Osborn

Abstract
The serological diagnosis of juvenile rheumatoid arthritis (JRA) is difficult, with only 7–10% of patients 19S IgM rheumatoid factor positive. About 60–70% of patients are positive for hidden 19S IgM rheumatoid factor, but this test requires serum separation and is not available in most laboratories. Antiperinuclear factor has been described in both seropositive and seronegative adult patients with rheumatoid arthritis, but has not been thoroughly evaluated in children with JRA. This study determined the diagnostic sensitivity and specificity of antiperinuclear factor in patients with JRA.

Serum samples from 64 children with JRA, 24 with systemic lupus erythematosus (SLE), and 24 control subjects were tested for the presence of antiperinuclear factor. A total of 10 (83%) of seropositive, polyarticular onset and six (37%) of seronegative, polyarticular onset patients with JRA were positive for antiperinuclear factor. The occurrence of antiperinuclear factor in five (19%) with pauciarticular onset and one (10%) with systemic onset (JRA) as well as in four (17%) with SLE was not increased compared with the control subjects (1/24 (4%)).

These data show an overall diagnostic sensitivity and specificity of 34 and 90% respectively in this group of patients. Although less sensitive than the hidden rheumatoid factor assay, the antiperinuclear factor assay is easier to perform and may contribute to the serological diagnosis of JRA.

Antiperinuclear factor is an antibody (or antibodies) that binds to 0·2–3·0 μm keratohyaline granules surrounding nuclei of human buccal mucosal cells. The biochemical nature of the antigen is unknown. It stains positively with methylene blue and periodic acid-Schiff and does not contain DNA or RNA. Antiperinuclear factor has been found in 48–92% of patients with rheumatoid arthritis (RA), mostly in patients seropositive for 19S lgM rheumatoid factor, but also in 10–76% of seronegative patients. Its occurrence in healthy adult controls and patients with other connective tissue diseases is in the range 0–14%. However, one study reported a higher frequency in patients with systemic lupus erythematosus (SLE) and scleroderma (46 and 26% respectively). The presence of antiperinuclear factor correlates with disease severity and also with the presence of rheumatoid factor and HLA-DR4. Data for antiperinuclear factor in children have only been reported by Janssens et al, who found three positive antiperinuclear factor reactions in 13 patients with juvenile rheumatoid arthritis (JRA).

In the present study, we determined the occurrence of antiperinuclear factor in four different onset types of JRA, in children with SLE, and in healthy control children to establish whether the antiperinuclear factor assay can aid in the diagnosis of JRA.

Materials and methods

PATIENTS AND CONTROLS
Serum samples were collected from 112 children: 26 had pauciarticular onset JRA, 12 had seropositive and 16 had seronegative polyarticular onset JRA, 10 had systemic onset JRA, and 24 had SLE. The control subjects were 24 children with non-inflammatory musculoskeletal symptoms. Patients with JRA and SLE met the respective criteria of the American College of Rheumatology. All patients were followed up at the St Louis University Rheumatology Clinic, at the Cardinal Glennon Children’s Hospital, or the St. Louis University Doctors’ Office Building. The study was approved by the St. Louis University Institutional Review Board.

ANTIPERINUCLEAR FACTOR ASSAY
This was determined as previously described by Nienhuis and Mandema. Briefly, human buccal mucosal cells were obtained by scraping the inner side of the cheeks of healthy donors with a wooden tongue depressor, followed by rinsing in 0·15 mol/l phosphate buffered saline (pH 7.2). Cells were washed three times in phosphate buffered saline, spun onto a microscope slide using a cytopsin centrifuge, and fixed with acetone. After drying, the cell preparations were incubated for 90 minutes at room temperature with undiluted serum samples and serum samples diluted 1:5, 1:10, and 1:20. Fractions of selected serum samples were used when positive for antiperinuclear factor. Slides were washed three times with phosphate buffered saline, dried, and incubated with fluorescent antihuman gammaglobulins (Antibodies, Davis, CA, USA) for 30 minutes. The slides were then washed three times in phosphate buffered saline, air dried, mounted with glycerol, and studied with a fluorescence microscope (Laborlux II, Leitz). The fluorescence of perinuclear homogeneous spheres was considered to be a positive test for antiperinuclear factor.
Antiperinuclear factor in Juvenile Rheumatoid Arthritis

Presence of antiperinuclear factor in children with juvenile rheumatoid arthritis, systemic lupus erythematosus, and control subjects. Results given are number positive (%).

<table>
<thead>
<tr>
<th>Disease</th>
<th>Positive APF (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Undiluted serum</td>
</tr>
<tr>
<td>Juvenile rheumatoid arthritis</td>
<td></td>
</tr>
<tr>
<td>Polyarticular onset, seropositive (n=12)</td>
<td>10 (83)*</td>
</tr>
<tr>
<td>Polyarticular onset, seronegative (n=16)</td>
<td>6 (37)**</td>
</tr>
<tr>
<td>Pauciarticular onset (n=20)</td>
<td>5 (25)</td>
</tr>
<tr>
<td>Systemic onset (n=10)</td>
<td>1 (10)</td>
</tr>
<tr>
<td>Total (n=64)</td>
<td>22 (34)**</td>
</tr>
<tr>
<td>Systemic lupus erythematosus (n=24)</td>
<td>4 (17)</td>
</tr>
<tr>
<td>Control subjects (n=24)</td>
<td>1 (4)</td>
</tr>
</tbody>
</table>

APF=antiperinuclear factor. *p<0.001 vs controls; **p<0.05 vs controls.

Statistical analysis was performed using the χ² test with Yates’s correction.

Results

The occurrence of antiperinuclear factor in the four onset types of patients with JRA, children with SLE, and control subjects is shown in the table. The presence of antiperinuclear factor was increased in undiluted samples of seropositive, polyarticular onset JRA (83%). The occurrence in seronegative, polyarticular onset JRA was less (37%), whereas the occurrence in pauciarticular onset, systemic onset JRA and SLE did not differ from that of the control subjects. The reactivity was unchanged at the 1:5 dilution, but, in most samples, decreased with further dilution of the serum samples. Only two samples showed the ‘prozone effect’ described by Westgeest et al., these were antiperinuclear factor positive only at higher dilutions (1:10 and above).

The overall sensitivity of the test was 34% in undiluted serum samples, decreasing to 38% with the 1:5 dilution. The specificity in the groups that were tested was 90% (undiluted samples), increasing to 96% with the 1:5 dilution.

Discussion

This is the first known report of the presence of antiperinuclear factor in a large number of children with JRA or SLE. The overall presence of antiperinuclear factor in patients with JRA (34%) was lower than reported in adult patients with RA; however, the presence in seropositive patients with polyarticular onset JRA (83%) was comparable. These results are similar to those of Janssens et al who previously found antiperinuclear factor in 3/13 patients with JRA, all of whom were rheumatoid factor positive. Antiperinuclear factor was also noted in 19% of patients with pauciarticular onset JRA. These patients are being monitored to see if they develop polyarticular disease. If so, the test might have implications for starting treatment with disease modifying drugs earlier. The occurrence of antiperinuclear factor in children with SLE and controls was low and similar to that reported in adults.

The presence of antiperinuclear factor principally in patients with polyarticular onset JRA supports the view that there are different aetiologies for the various onset types of JRA. It is also another parameter indicating the similarity between polyarticular onset JRA and adult RA. Regarding its diagnostic value, antiperinuclear factor does not offer an advantage over the hidden rheumatoid factor assay in diagnosing JRA. Hidden rheumatoid factor is positive in 60–70% of patients with JRA and correlates with disease activity. However, the test is time consuming and is not available in most laboratories, whereas the antiperinuclear factor test is easier to perform.

Antiperinuclear factor tests can be performed in any laboratory capable of carrying out tests for antinuclear antibodies. It should be noted that the proportion of antigen positive donors in the normal population is high, but only a small percentage of these have enough antigen to allow the easy detection of antiperinuclear factor. The test is reproducible and seems to be highly specific for JRA and RA. Although less sensitive in patients with JRA than RA, it can still serologically diagnose a third of polyarticular onset, seronegative patients, in addition to being positive in almost all seropositive patients. Thus, if used in addition to rheumatoid factor testing, it may contribute to the serological diagnosis of patients suspected of having JRA. Further testing comparing groups with other arthritides, such as viral arthritis, are necessary to establish the specificity of this test.

Supported in part by grants from Employees Charity Services of the McDonnell-Douglas Corporation of St Louis, the Eastern Missouri Chapter of The Arthritis Foundation, and the Eastern Missouri Chapter of the Lupus Foundation of America, Inc.

7 Janssens X, Veys E M, Verbruggen G, DeClercq L. The